LOGIN  |  REGISTER
Surmodics

argenx (NASDAQ: ARGX) Stock Quote

Last Trade: US$387.00 -1.34 -0.35
Volume: 194,160
5-Day Change: 0.05%
YTD Change: 1.73%
Market Cap: US$23.000B

Latest News From argenx

June 4, 2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL. A live webcast of the fireside chat may... Read More
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The... Read More
May 7, 2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may... Read More
May 2, 2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may... Read More
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe... Read More
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development... Read More
March 26, 2024 - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and... Read More
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024 7:00 AM CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that... Read More
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients March 7, 2024, 10:01 pm CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people... Read More
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management to host conference call today at 2:30 pm CET (8:30 am ET) February 29, 2024, 7:00 am CET - Amsterdam, the Netherlands – argenx SE... Read More
February 26, 2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: TD Cowen 44 th Annual Health Care Conference. Fireside chat on Monday, March 4, 2024 at 11:10 a.m. ET in Boston,... Read More
February 22, 2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update. A... Read More
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART ® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and... Read More
Availability of VYVGART ® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET, Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of Health, Labour and... Read More
Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART ® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN Data from six Phase 2 proof-of-concept trials expected by end of 2024 Nominated four new pipeline candidates with IND... Read More
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT. A live webcast of the presentation may be accessed on the Investor... Read More
ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET) Regulated Information – Inside Information December 20, 2023, 7:00am CET - AMSTERDAM, THE NETHERLANDS — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the... Read More
Study did not meet primary or secondary endpoints Favorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET) Regulated information – Inside information November 28, 2023, 7:00am CET - Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people... Read More
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enable broad access to VYVGART SC for eligible patients Amsterdam, The Netherlands— November 16, 2023 — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from... Read More
November 1, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November: Guggenheim 5th Annual Inflammation & Immunology Conference. Fireside chat on Tuesday, November 7, 2023 at 10:30 a.m.... Read More
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia gravis (gMG) Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data Data across multiple indications and dosing schedules confirm favorable safety... Read More
$329 million in third quarter global net product sales On track to submit VYVGART ® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host conference call today at 1:30 pm CET (8:30 am ET) October 31, 2023, Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe... Read More
October 24, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET (8:30 am ET) to discuss its third quarter 2023 financial results and provide a business update. A webcast of the live... Read More
VYVGART Ⓡ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated patients were responders on the MG-ADL scale compared to 30% of placebo patients after one treatment cycle Amsterdam, The Netherlands —Sep. 21, 2023— argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving... Read More
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administration European Commission (EC) decision on marketing authorization application (MAA) expected within approximately 60 days Amsterdam, The Netherlands—September 15, 2023— argenx SE (Euronext & Nasdaq: ARGX), a global immunology... Read More
August 30, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in September: Citi's 18th Annual BioPharma Conference. Fireside chat on Wednesday, September 6, 2023 at 4:20 p.m. ET in Boston, MA.... Read More
$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in July Global VYVGART expansion continued with commercial launch in Italy and distribution agreement with Handok in South Korea Topline results from ADVANCE-SC and ADDRESS expected in fourth quarter of 2023 Management to host conference call today at 2:30 pm CET (8:30... Read More
Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the closing of its previously announced global offering of an aggregate of 2,581,633 ordinary shares, which may be represented by American Depositary Shares (“ADSs”) and which includes full exercise of the underwriters’ option to... Read More
July 20, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET (8:30 am ET) to discuss its half year 2023 financial results and provide a second quarter business update. A webcast of the... Read More
Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (“ADSs”)) have exercised in full their option to purchase 336,734 additional... Read More
Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares (“ADSs”). The global offering is comprised of an offering of ordinary shares represented by ADSs in the United States and... Read More
Regulated information — Inside information July 17, 2023 - Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that it has commenced a global offering of $750 million (approximately €668.6 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”).... Read More
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology Favorable safety and tolerability profile consistent with previous clinical trials and confirmed safety profile of VYVGART ® Conference call scheduled for today, July 17, 2023 at 8:30am ET... Read More
First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT trial Zai Lab to seek National Reimbursement Drug List (NRDL) inclusion for... Read More
VYVGART ® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) With this approval, argenx broadens innovative gMG product offering and demonstrates continued commitment to providing more choice and flexibility for patients Efficacy of VYVGART Hytrulo was established by demonstrating a comparable pharmacodynamic (PD) effect to VYVGART ® in Phase 3 ADAPT-SC bridging study... Read More
Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in the first dose cohort Early efficacy signals support proof-of-concept of empasiprubart in multifocal motor neuropathy Regulated Information/Inside Information Amsterdam, the Netherlands—June 20, 2023— argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people... Read More
May 31, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in two upcoming investor conferences in June: William Blair 43 rd Annual Growth Stock Conference . Presentation on Tuesday, June 6, 2023 at 1:20 p.m. CT in Chicago, IL.... Read More
$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison 88 events achieved in ADHERE trial; topline data now expected in July 2023 Enrollment completed in ADVANCE-SC and ADDRESS trials; topline data from both expected in fourth quarter of 2023 Management to host conference call today at 2:30 pm CET (8:30 am... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held yesterday. All items on the agenda received a majority of votes in favor except for agenda item 3 (advisory non-binding vote on the 2022 remuneration report). As part of the... Read More
May 2, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV. A live webcast of the fireside chat may be... Read More
April 27, 2023 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2023 financial results and provide a business update. A webcast of the live call... Read More
Amsterdam, the Netherlands - 04/18/2023 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will present six abstracts further demonstrating its long-term commitment to the generalized myasthenia gravis (gMG) community during the 75th American Academy of Neurology (AAN) Annual Meeting, which is taking... Read More
Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands – 04/17/2023 argenx SE (Euronext & Nasdaq: ARGX) and Genmab A/S (Nasdaq: GMAB) announced today that argenx and Genmab have entered into a collaboration agreement to jointly... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons... Read More
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo... Read More
$173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023; MAA filed in Japan with approval decision expected by first quarter of 2024 ADHERE topline results continue to be expected in second quarter of 2023 Karen Massey appointed as Chief Operating Officer as part of... Read More
Karen Massey appointed as Chief Operating Officer, effective March 13, 2023 Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 - Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey will join argenx as Chief Operating Officer,... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance... Read More
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March: Cowen 43rd Annual Healthcare Conference . Fireside chat on Monday, March 6, 2023 at 10:30 a.m. ET in Boston, MA. Raymond James 44th Annual... Read More
February 23, 2023- Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET (8:30 am ET) to discuss its full year 2022 financial results and provide a fourth quarter business update. A webcast of... Read More
Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Biologics License Application (BLA) for subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other... Read More
Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B enrollment has surpassed projected target of 130 patients Registrational trial of efgartigimod in thyroid eye disease (TED) to start in 2023; additional proof-of-concept trials to start in ANCA-associated vasculitis and antibody mediated rejection (AMR) Submission for marketing... Read More
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT. A live webcast of the presentation may be accessed on the Investors... Read More
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of... Read More
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease VYVGART showed rapid, clinically and statistically significant improvements in platelet counts compared with placebo; safety profile consistent with previous trials Topline data from ADVANCE-SC trial of subcutaneously (SC) administered VYVGART for ITP expected in second half... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB